LINK ALTERNATIF MBL77 OPTIONS

Besides ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and healthy enough to tolerate FCR therapy, should still be very good candidates with the latter, with the advantage being this therapy could be concluded in six months although ibrutinib should be taken indefinitely. This option can be especially valuable for non-compliant clients